Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
upifitamab rilsodotin (XMT-1536) / Mersana
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer	Terminated	3	20	Canada, US, RoW	Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo	Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)	High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	09/23	09/23
2021-005099-21: Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)	Not yet recruiting	3	581	Europe	Upifitamab rilsodotin, XMT-1536, Powder for solution for infusion	Mersana Therapeutics, Inc., Mersana Therapeutics Inc, Mersana Therapeutics, Inc., Mersana Therapeutics, Inc	Recurrent, Platinum-Sensitive Ovarian Cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b	Active, not recruiting	1/2	523	US	upifitamab rilsodotin, XMT-1536, UpRi	Mersana Therapeutics	Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic	05/23	10/24
NCT06517433: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b	Completed	1	62	US	upifitamab rilsodotin, XMT-1536, UpRi	Mersana Therapeutics	Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic	07/21	07/21
NCT06517485: First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b	Completed	1	142	US	upifitamab rilsodotin, XMT-1536, UpRi	Mersana Therapeutics	Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma	05/22	08/22
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer	Terminated	1	31	US	XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin	Mersana Therapeutics, IQVIA Biotech, PSI CRO	Platinum-sensitive Ovarian Cancer (UPGRADE-A)	10/23	10/23